GSA Capital Partners’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$606K Sell
44,005
-71,530
-62% -$1.06M 0.04% 928
2026
Q2
$1.84M Sell
115,535
-2,137
-2% -$34.4K 0.12% 198
2026
Q1
$1.55M Buy
117,672
+87,751
+293% +$1.32M 0.1% 264
2025
Q4
$462K Sell
29,921
-24,615
-45% -$329K 0.04% 874
2025
Q3
$562K Buy
54,536
+1,323
+2% +$12.5K 0.05% 768
2025
Q2
$593K Sell
53,213
-1,855
-3% -$23.2K 0.04% 806
2025
Q1
$677K Sell
55,068
-1,316
-2% -$16.5K 0.06% 588
2024
Q4
$631K Buy
+56,384
New +$490K 0.05% 728

Other funds holding NPCE

GSA Capital Partners's NPCE Position: Q3 2026 in Review

GSA Capital Partners reduced its Neuropace (NPCE) stake by 62% in Q3 2026, selling an estimated $1.06M and leaving 44,005 shares worth $606K. The position accounts for 0.04% of the portfolio, ranked #928.

GSA Capital Partners first reported a position in NPCE in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.84M in Q2 2026. 99 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • GSA Capital Partners held 44,005 shares of Neuropace worth $606K as of Q3 2026.
  • GSA Capital Partners sold 71,530 Neuropace shares in Q3 2026, an estimated $1.06M.
  • Neuropace made up 0.04% of GSA Capital Partners's portfolio in Q3 2026, its #928 holding.
  • GSA Capital Partners first reported a position in Neuropace in Q4 2024 and has held it in 8 quarters since.
  • GSA Capital Partners's Neuropace position peaked at $1.84M in Q2 2026.
  • 99 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.